

hereby incorporated herein by reference. In addition, The above-mentioned applications, as well as all documents cited herein and documents referenced or cited in documents cited herein, are hereby incorporated herein by reference.--


# IN THE CLAIMS:

Kindly amend the claims, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

Kindly cancel claims 1-5 without prejudice.

Kindly add new claims 6-20, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

6. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound of the formula




wherein each of R<sub>1</sub> and R<sub>2</sub> is independently selected from H, alkyl, alkenyl, cycloalkyl and aryl; wherein at least one of R<sub>1</sub> and R<sub>2</sub> is H; and

wherein the group Polycycle is a ring system comprising at least four rings, at least two of which are fused;

wherein the compound is an inhibitor of an enzyme having steroid sulphatase activity (E.C.3.1.6.2);

wherein if the sulphamate group on the compound were to be replaced with a sulphate group to form a sulphate compound and incubated with a steroid sulphatase enzyme (E.C.3.1.6.2) at a pH 7.4 and 37°C it would provide a K<sub>m</sub> value of less than 50 μM.

7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound comprising a steroidal ring structure and a sulphamate group of the formula




wherein each of R<sub>1</sub> and R<sub>2</sub> is independently selected from H, alkyl, alkenyl, cycloalkyl and aryl; wherein at least one of R<sub>1</sub> and R<sub>2</sub> is H; and

wherein the compound is an inhibitor of an enzyme having steroid sulphatase activity (E.C.3.1.6.2);

wherein if the sulphamate group on the compound were to be replaced with a sulphate group to form a sulphate compound and incubated with a steroid sulphatase enzyme (E.C.3.1.6.2) at a pH 7.4 and 37°C it would provide a  $K_m$  value of less than 50  $\mu$ M.

8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound of the formula



wherein each of  $R_1$  and  $R_2$  is independently selected from H, alkyl, alkenyl, cycloalkyl and aryl; wherein at least one of  $R_1$  and  $R_2$  is H; and

wherein the group Polycycle is a ring system comprising at least three rings, at least two of which are fused;

wherein the compound is an inhibitor of an enzyme having steroid sulphatase activity (E.C.3.1.6.2);

wherein if the sulphamate group on the compound were to be replaced with a sulphate group to form a sulphate compound and incubated with a steroid sulphatase enzyme (E.C.3.1.6.2) at a pH 7.4 and 37°C it would provide a  $K_m$  value of less than 50  $\mu$ M;

wherein the compound is present in an amount to provide 100-500 mg of compound per unit dose.

9. A pharmaceutical composition according to claim 6 or 8, wherein the group Polycycle is a ring system comprising at least four rings, at least three of which are fused.

10. A pharmaceutical composition according to claim 7, wherein the steroidal ring structure is a residue of a 3-sterol.

11. A pharmaceutical composition according to claim 10, wherein the sterol is selected from the group consisting of oestrone, dehydroepiandrosterones, substituted oestrones and substituted dehydroepiandrosterones.

12. A pharmaceutical composition according to any one of claims 6 to 11 wherein  $R_1$  and  $R_2$  are independently selected from H, or a  $C_1$ - $C_{10}$  alkyl; but wherein at least one of  $R_1$  and  $R_2$  is H.

Q2  
Cont

205220 "SE248001

13. A pharmaceutical composition according to any one of claims 6 to 12 wherein  $R_1$  and  $R_2$  are independently selected from H, or  $C_1$ - $C_5$  alkyl; but wherein at least one of  $R_1$  and  $R_2$  is H.


14. A pharmaceutical composition according to any one of claims 6 to 13 wherein  $R_1$  and  $R_2$  are independently selected from H or methyl; but wherein at least one of  $R_1$  and  $R_2$  is H.

15. A pharmaceutical composition according to any one of claims 6 to 12 wherein  $R_1$  is H and  $R_2$  is H.

16. A pharmaceutical composition according to any one of claims 6 to 15 wherein the compound is any one of oestrone 3-sulphamate, oestrone-3-N,N-dimethylsulphamate, oestrone-3-N-monomethylsulphamate.

17. A pharmaceutical composition according to claim 6 or 8 wherein the group Polycycle represents the residue of a sterol.


18. A pharmaceutical composition according to claim 7 wherein the compound is a compound of the formula



wherein the group Polycycle represents the residue of a sterol, and wherein  $R_1$  and  $R_2$  are as defined in claim 7.

19. A pharmaceutical composition according to claim 17 or 18, wherein the sterol is a 3-sterol.

20. A pharmaceutical composition according to claim 7 wherein the compound is a compound of the formula



wherein the group Polycycle represents the residue of a 3-sterol, and wherein  $R_1$  and  $R_2$  are H.--